Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tipifarnib; Zarnestra; R115777 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Tipifarnib;Zarnestra; R115777 | DRUG | - |
Inclusion Criteria: * Newly diagnosed or re-lapsing AML * Patient not medically fit for combination induction chemotherapy * Pathologic confirmation of AML (= or \> 20% bone marrow leukemic blasts) * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. Exclusion Criteria: * Pr...
Tipifarnib, also known as Zarnestra or R115777, is an investigational small molecule being studied for the treatment of Acute Myeloid Leukemia (AML). It is currently in Phase 3 clinical development and has not been approved by the FDA.
Tipifarnib is a small molecule that targets farnesyltransferase, an enzyme involved in cell signaling. By inhibiting this enzyme, it aims to disrupt cancer cell growth and survival in Acute Myeloid Leukemia.
Tipifarnib is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 3 clinical trials for Acute Myeloid Leukemia.
Tipifarnib is in Phase 3 clinical development for Acute Myeloid Leukemia. It is an investigational drug and has not received FDA approval. One Phase 3 trial has been completed, with no active trials currently ongoing.
Tipifarnib has one completed Phase 3 trial, NCT00093990, which compared Tipifarnib to best supportive care in newly diagnosed Acute Myeloid Leukemia patients aged 70 years and older. The trial enrolled 457 participants and was not blinded or controlled.
Yes, Tipifarnib is also known as Zarnestra and R115777. These names refer to the same investigational drug being developed by Johnson & Johnson for Acute Myeloid Leukemia.